Merck’s Molnupiravir (EIDD-281) Effective Against SARS-COV-2 | drbeen
Get free trial
with access to all our lectures
DrBeen Logo

no credit card required

My Notes

Become a member to create study notes.
Sign up for free trial
Merck’s Molnupiravir (EIDD-281) Effective Against SARS-COV-2 Duration: 29:11
Microbiology / Virology

Learning Objectives

Merck has a new drug molecule for SARS-COV-2. It is named Molnupiravir or EIDD-2801. We will discuss the following topics about this drug.


  1. Need for this anti-viral drug to be used with Remdesivir.
  2. History of the EIDD-2801.
  3. Trial for phase II and phase III.
  4. Route of administration.
  5. Drug properties.
  6. Mechanism of action.
  7. Results in mouse studies.
  8. Therapeutic index.


Dr. Mobeen Syed

Dr. Mobeen Syed

Mobeen Syed is the CEO of DrBeen Corp, a modern online medical education marketplace. Mobeen is a medical doctor and a software engineer. He graduated from the prestigious King Edward Medical University Lahore. He has been teaching medicine since 1994. Mobeen is also a software engineer and engineering leader. In this role, Mobeen has run teams consisting of hundreds of engineers and millions of dollars of budgets. Mobeen loves music, teaching, and doing business. He lives in Cupertino CA.

Videos in this series